RVMD

SEC source: 0001610717-24-000160 · form4.xml · derivative · entry 6

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,631

Underlying: Common Stock · 7,936 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.

SEC source: 0001610717-24-000160 · form4.xml · nonDerivative · entry 4

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 142,467

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.

F4 · price: This transaction was executed in multiple trades in prices ranging from $34.00 to $34.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2 · balance_after: Includes 100,013 restricted stock units.

SEC source: 0001610717-24-000160 · form4.xml · nonDerivative · entry 3

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,403

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.

F2 · balance_after: Includes 100,013 restricted stock units.

SEC source: 0001610717-24-000160 · form4.xml · derivative · entry 5

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,567

Underlying: Common Stock · 15,735 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.

SEC source: 0001610717-24-000160 · form4.xml · nonDerivative · entry 2

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 142,467

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.

F3 · price: This transaction was executed in multiple trades in prices ranging from $34.00 to $34.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2 · balance_after: Includes 100,013 restricted stock units.

SEC source: 0001610717-24-000160 · form4.xml · nonDerivative · entry 1

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 158,202

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.

F2 · balance_after: Includes 100,013 restricted stock units.

SEC source: 0001610717-24-000129 · form4.xml · derivative · entry 2

Wang Xiaolin · CIK 0001849181 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,700

Underlying: Common Stock · 84,700 shares

Expires 2034-02-28

F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001610717-24-000129 · form4.xml · nonDerivative · entry 1

Wang Xiaolin · CIK 0001849181 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,526

F1 · balance_after: Includes 62,513 restricted stock units.

F2 · balance_after: Includes 1,513 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2023.

SEC source: 0001610717-24-000130 · form4.xml · derivative · entry 2

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,400

Underlying: Common Stock · 92,400 shares

Expires 2034-02-28

F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001610717-24-000130 · form4.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,220

F1 · balance_after: Includes 63,726 restricted stock units.

F2 · balance_after: Includes 404 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2023.

SEC source: 0001610717-24-000131 · form4.xml · derivative · entry 2

Kelsey Stephen Michael · CIK 0001462808 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,900

Underlying: Common Stock · 179,900 shares

Expires 2034-02-28

F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001610717-24-000131 · form4.xml · nonDerivative · entry 1

Kelsey Stephen Michael · CIK 0001462808 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 273,032

F1 · balance_after: Includes 110,413 restricted stock units.

SEC source: 0001610717-24-000134 · form4.xml · derivative · entry 2

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,500

Underlying: Common Stock · 143,500 shares

Expires 2034-02-28

F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001610717-24-000134 · form4.xml · nonDerivative · entry 1

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,467

F1 · balance_after: Includes 100,013 restricted stock units.

SEC source: 0001610717-24-000133 · form4.xml · derivative · entry 5

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 314,000

Underlying: Common Stock · 314,000 shares

Expires 2034-02-28

F5 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001610717-24-000133 · form4.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 466,167

F1 · balance_after: Includes 248,000 restricted stock units.

SEC source: 0001610717-24-000132 · form4.xml · derivative · entry 2

Cislini Jeff · CIK 0001969082 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,500

Underlying: Common Stock · 73,500 shares

Expires 2034-02-28

F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001610717-24-000132 · form4.xml · nonDerivative · entry 1

Cislini Jeff · CIK 0001969082 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,126

F1 · balance_after: Includes 52,417 restricted stock units.

SEC source: 0001610717-24-000040 · form4.xml · nonDerivative · entry 1

Cislini Jeff · CIK 0001969082 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,126

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2023.

F2 · balance_after: Includes 31,417 restricted stock units.

F3 · balance_after: Includes 342 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2023.

SEC source: 0001610717-24-000025 · form4.xml · nonDerivative · entry 1

Kelsey Stephen Michael · CIK 0001462808 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 221,632

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 14, 2022.

F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 59,013 restricted stock units.

SEC source: 0001610717-24-000008 · form4.xml · nonDerivative · entry 1

Kelsey Stephen Michael · CIK 0001462808 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 224,969

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 14, 2022.

F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 59,013 restricted stock units.

SEC source: 0001610717-23-000425 · form4.xml · nonDerivative · entry 1

Kelsey Stephen Michael · CIK 0001462808 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 238,299

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 14, 2022.

F2 · price: The transaction was executed in multiple trades in prices ranging from $29.00 to $29.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 59,013 restricted stock units.

SEC source: 0001610717-23-000407 · form4.xml · nonDerivative · entry 3

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,467

F4 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of RSUs after July 15, 2023.

F5 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

F6 · price: This transaction was executed in multiple trades in prices ranging from $25.9016 to $25.9219, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2 · balance_after: Includes 59,013 restricted stock units ("RSUs").

SEC source: 0001610717-23-000416 · form4.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,416

F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

F3 · price: This transaction was executed in multiple trades in prices ranging from $25.9017 to $25.9385, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4 · balance_after: Includes 37,326 RSUs.

SEC source: 0001610717-23-000413 · form4.xml · nonDerivative · entry 1

Kelsey Stephen Michael · CIK 0001462808 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 271,633

F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

F3 · price: The transaction was executed in multiple trades in prices ranging from $25.8901 to $25.909, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4 · balance_after: Includes 59,013 RSUs.

SEC source: 0001610717-23-000415 · form4.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 376,167

F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

F3 · price: This transaction was executed in multiple trades in prices ranging from $25.8996 to $25.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4 · balance_after: Includes 158,000 RSUs.

SEC source: 0001610717-23-000414 · form4.xml · nonDerivative · entry 1

Cislini Jeff · CIK 0001969082 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,284

F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

F3 · price: This transaction was executed in multiple trades in prices ranging from $25.9017 to $25.915, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4 · balance_after: Includes 31,417 RSUs.

SEC source: 0001610717-23-000407 · form4.xml · derivative · entry 4

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,302

Underlying: Common Stock · 5,000 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.

SEC source: 0001610717-23-000407 · form4.xml · nonDerivative · entry 2

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,460

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.

F3 · price: This transaction was executed in multiple trades in prices ranging from $26.04 to $26.93, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2 · balance_after: Includes 59,013 restricted stock units ("RSUs").

SEC source: 0001610717-23-000407 · form4.xml · nonDerivative · entry 1

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,460

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.

F2 · balance_after: Includes 59,013 restricted stock units ("RSUs").

SEC source: 0001610717-23-000393 · form4.xml · derivative · entry 3

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,302

Underlying: Common Stock · 5,000 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.

SEC source: 0001610717-23-000393 · form4.xml · nonDerivative · entry 2

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,460

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.

F2 · balance_after: Includes 64,875 restricted stock units.

SEC source: 0001610717-23-000393 · form4.xml · nonDerivative · entry 1

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,460

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.

F2 · balance_after: Includes 64,875 restricted stock units.

SEC source: 0001610717-23-000360 · form4.xml · nonDerivative · entry 1

Cislini Jeff · CIK 0001969082 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,513

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2023.

F2 · price: This transaction was executed in multiple trades in prices ranging from $21.38 to $22.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 34,860 restricted stock units.

SEC source: 0001610717-23-000356 · form4.xml · derivative · entry 5

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,800

Underlying: Common Stock · 36,800 shares

Expires 2033-11-08

F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of November 8, 2023, subject to the reporting person's continued employment or service relationship with the Company on each such vesting date.

SEC source: 0001610717-23-000356 · form4.xml · derivative · entry 4

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,651

Underlying: Common Stock · 10,651 shares

Expires 2024-12-17

F4 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 95,784 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 10,651 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving her interests in the Earn-out Shares.

F4 · price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 95,784 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 10,651 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving her interests in the Earn-out Shares.

F4 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 95,784 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 10,651 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving her interests in the Earn-out Shares.

SEC source: 0001610717-23-000356 · form4.xml · nonDerivative · entry 3

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,487

F3 · balance_after: Includes 10,500 restricted stock units.

SEC source: 0001610717-23-000356 · form4.xml · nonDerivative · entry 2

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,987

F2 · shares: Pursuant to the Merger Agreement, at the Effective Time, a stock option to purchase shares of EQRx, Inc. common stock that was outstanding immediately prior to the Effective Time was cancelled and converted automatically into the right to receive 27,696 shares of the Company's common stock. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, a stock option to purchase shares of EQRx, Inc. common stock that was outstanding immediately prior to the Effective Time was cancelled and converted automatically into the right to receive 27,696 shares of the Company's common stock. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

SEC source: 0001610717-23-000356 · form4.xml · nonDerivative · entry 1

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,291

F1 · shares: Pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the "Merger Agreement"), at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the "Merger Agreement"), at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

SEC source: 0001610717-23-000355 · form4.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 296,039

Underlying: Common Stock · 296,039 shares

Expires 2024-12-17

F3 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares.

F3 · kind: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares.

F3 · price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares.

F3 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares.

SEC source: 0001610717-23-000355 · form4.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,331,494

F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 31, 2023, at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 31, 2023, at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F2 · balance_after: Includes 5,200 restricted stock units.

SEC source: 0001610717-23-000354 · form4.xml · derivative · entry 5

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Nextech VI Oncology SCSp

Disclosed balance after: 70,035

Underlying: Common Stock · 70,035 shares

Expires 2024-12-17

F6 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), Nextech VI was allocated the right to acquire an aggregate of 629,803 Earn-out Shares. At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of Nextech VI 70,035 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The Nextech VI has signed a waiver and release waiving its interests in the Earn-out Shares.

F6 · kind: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), Nextech VI was allocated the right to acquire an aggregate of 629,803 Earn-out Shares. At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of Nextech VI 70,035 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The Nextech VI has signed a waiver and release waiving its interests in the Earn-out Shares.

F6 · price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), Nextech VI was allocated the right to acquire an aggregate of 629,803 Earn-out Shares. At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of Nextech VI 70,035 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The Nextech VI has signed a waiver and release waiving its interests in the Earn-out Shares.

F6 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), Nextech VI was allocated the right to acquire an aggregate of 629,803 Earn-out Shares. At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of Nextech VI 70,035 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The Nextech VI has signed a waiver and release waiving its interests in the Earn-out Shares.

F3 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001610717-23-000354 · form4.xml · derivative · entry 4

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Nextech V Oncology S.C.S., SICAV-SIF

Disclosed balance after: 120,683

Underlying: Common Stock · 120,683 shares

Expires 2024-12-17

F5 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), Nextech V was allocated the right to acquire an aggregate of 1,085,271 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of Nextech V 120,683 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The Nextech V has signed a waiver and release waiving its interests in the Earn-out Shares.

F5 · kind: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), Nextech V was allocated the right to acquire an aggregate of 1,085,271 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of Nextech V 120,683 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The Nextech V has signed a waiver and release waiving its interests in the Earn-out Shares.

F5 · price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), Nextech V was allocated the right to acquire an aggregate of 1,085,271 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of Nextech V 120,683 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The Nextech V has signed a waiver and release waiving its interests in the Earn-out Shares.

F5 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), Nextech V was allocated the right to acquire an aggregate of 1,085,271 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of Nextech V 120,683 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The Nextech V has signed a waiver and release waiving its interests in the Earn-out Shares.

F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001610717-23-000354 · form4.xml · nonDerivative · entry 2

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Nextech VI Oncology SCSp

Disclosed balance after: 1,153,293

F1 · shares: Pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the "Merger Agreement"), at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the "Merger Agreement"), at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F3 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001610717-23-000354 · form4.xml · nonDerivative · entry 1

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Nextech V Oncology S.C.S., SICAV-SIF

Disclosed balance after: 3,590,313

F1 · shares: Pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the "Merger Agreement"), at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the "Merger Agreement"), at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001610717-23-000315 · form4.xml · derivative · entry 2

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,941

Underlying: Common Stock · 7,500 shares

Expires 2028-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001610717-23-000315 · form4.xml · nonDerivative · entry 1

Horn Margaret A · CIK 0001294192 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,460

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 64,875 restricted stock units.

SEC source: 0001610717-23-000314 · form4.xml · derivative · entry 5

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,446

Underlying: Common Stock · 35,000 shares

Expires 2027-03-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001610717-23-000314 · form4.xml · nonDerivative · entry 1

GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 384,332

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 174,000 restricted stock units.

SEC source: 0001610717-23-000313 · form4.xml · derivative · entry 4

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,137 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.